Hofseth BioCare ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
For the six months, sales was NOK 95.3 million compared to NOK 55.49 million a year ago. Revenue was NOK 121.2 million compared to NOK 56.62 million a year ago. Net loss was NOK 32.07 million compared to NOK 64.05 million a year ago. Basic loss per share from continuing operations was NOK 0.08 compared to NOK 0.18 a year ago. Diluted loss per share from continuing operations was NOK 0.08 compared to NOK 0.18 a year ago.